Spero Therapeutics, Inc.

NASDAQ:SPRO

Biotechnology

Healthcare
$0.87 +3.79%

+$0.08 today

Market cap
$50.92M
Beta
1.46
P/E (TTM)
8.2
EPS (TTM)
$0.27
52W Low $1.80High $3.22

Volume 0.27M

Average 0.78M

SPRO Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Spero Therapeutics, Inc.NASDAQ: SPRO

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $4.89M fell 28.4% year over year, behind the -21.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 13.7% from the prior quarter. Over 3 fiscal years it compounded at -16.6% a year.

Context

  • Selling, general & admin amounted to 35.5% of revenue in FY2025, down 13.9 pp from a year earlier.
  • Selling, general & admin increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 1 analysts of $925.79K (-95.6%) for the fiscal year ending Dec 2026, a slowdown from the -10.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.89M+13.7% QoQ
Last fiscal yearDec 2025
$21.18M-10.7% YoY
LTMMar 2026
$19.24M-21.8% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-28.4%-100.0%-71.6 pp
1 year-10.7%-95.6%-85.0 pp
3-year CAGR-16.6%+69.0%+85.5 pp
5-year CAGR+5.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
21.18M USD
Year-over-year change
-10.7%
4-year CAGR
-15.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How SPRO compares with its peers on the latest reported figures

  • SPRO's LTM Mar 2026 selling, general & admin of $19.24M is the 5th highest of the 10 companies compared; the peer median is $18.46M.
  • Its year-over-year change of -21.8% is the 7th highest of 10, against a peer median of -7.7%.
  • Selling, general & admin amounts to 35.1% of revenue for SPRO, versus a peer median of 269.8%.
SPRO Competitors Peer median
Selling, General & Admin for SPRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$16.46B +48531.9%-28.7%—
SEERSeer, Inc.LTM Mar 2026$40.57M -24.5%-6.8%269.8%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$35.34M -27.5%-17.7%3080.9%
IRDOpus Genetics, Inc.LTM Mar 2026$21.57M +8.6%+44.6%180.0%
SPROSpero Therapeutics, Inc.LTM Mar 2026$19.24M -21.8%-16.6%35.1%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$18.46M -7.7%+13.7%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$15.52M -5.5%-6.6%—
ACTUActuate Therapeutics IncLTM Mar 2026$12.2M +39.9%+47.3%—
CGTXCognition Therapeutics, Inc.LTM Mar 2026$10.32M -12.0%-7.1%—
HURATuHURA Biosciences, Inc.LTM Mar 2026$3.55M -47.4%+11.8%—
Peer median (excluding SPRO) $18.46M-7.7%-6.6%269.8%

Competitors are the stored peer set for SPRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.07M48.58M103.78M47.98M59.62M
Cost of Revenue0051.44M96.76M0
Gross Profit3.07M48.58M52.34M(48.78M)59.62M
Gross Margin100.0%100.0%50.4%-101.7%100.0%
Research & Development64.53M47.59M51.44M96.76M38.47M
Selling, General & Admin41.7M36.48M25.55M23.7M21.18M
Operating Expenses91.04M90.78M30.86M24.58M59.64M
Depreciation & Amortization646K869K367K2K0
EBITDA(87.17M)(42.94M)27.15M(72.48M)8.83M
EBITDA Margin-2839.4%-88.4%26.2%-151.1%14.8%
Operating Income(87.97M)(42.2M)21.48M(73.36M)(24K)
Operating Margin-2865.5%-86.9%20.7%-152.9%-0.0%
Interest Income346K1.11M3.94M4.74M2.51M
Interest Expense1.94M2.61M000
Other Income / Expenses(1.79M)(4.22M)3.92M4.8M8.86M
Income Before Tax(89.76M)(46.42M)25.4M(68.57M)8.83M
Pre-Tax Margin-2923.6%-95.5%24.5%-142.9%14.8%
Income Tax Expense002.6M0261K
Net Income(89.76M)(46.42M)22.81M(68.57M)8.57M
Net Margin-2923.6%-95.5%22.0%-142.9%14.4%
EPS (Basic)(2.91)(1.23)0.43(1.27)0.15
EPS (Diluted)(2.91)(1.23)0.43(1.27)0.15
Weighted Avg Shares30.9M37.59M52.7M54.04M56.02M
Weighted Avg Shares (Diluted)30.9M37.59M52.99M54.04M59.04M

Spero Therapeutics, Inc.

NASDAQ:SPRO

Intrinsic Alpha fair value

Locked

Current Price

$0.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.